{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:10:47Z","timestamp":1789668647198,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20226-x","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:16:05Z","timestamp":1784049365000},"page":"8799-8806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab\/Bevacizumab"],"prefix":"10.1245","volume":"33","author":[{"given":"Junichi","family":"Shindoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"20226_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"20226_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"20226_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3350\/cmh.2025.0724","volume":"31","author":"IC Lee","year":"2025","unstructured":"Lee IC, Wang HW, Teng W, et al. Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma. Clin Mol Hepatol. 2025;31:1213\u201332.","journal-title":"Clin Mol Hepatol"},{"key":"20226_CR4","first-page":"779","volume":"14","author":"J Zhou","year":"2025","unstructured":"Zhou J, Sun H, Wang Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma. Liver Cancer. 2025;14:779\u2013835.","journal-title":"Liver Cancer"},{"key":"20226_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/jhbp.1135","volume":"29","author":"J Arita","year":"2022","unstructured":"Arita J, Ichida A, Nagata R, et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. J Hepatobiliary Pancreat Sci. 2022;29:732\u201340.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"20226_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/apt.18237","volume":"60","author":"T Hatanaka","year":"2024","unstructured":"Hatanaka T, Kakizaki S, Hiraoka A, et al. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: comparative analysis of conversion, partial response and complete response patients. Aliment Pharmacol Ther. 2024;60:1361\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"20226_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s11605-022-05388-9","volume":"26","author":"J Shindoh","year":"2022","unstructured":"Shindoh J, Kawamura Y, Kobayashi M, et al. Prognostic advantages of individual additional interventions after lenvatinib therapy in patients with advanced hepatocellular carcinoma. J Gastrointest Surg. 2022;26:1637\u201346.","journal-title":"J Gastrointest Surg"},{"key":"20226_CR8","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.1245\/s10434-021-09974-0","volume":"28","author":"J Shindoh","year":"2021","unstructured":"Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28:7663\u201372.","journal-title":"Ann Surg Oncol"},{"key":"20226_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10147-022-02229-2","volume":"27","author":"S Itoh","year":"2022","unstructured":"Itoh S, Toshida K, Morita K, et al. Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. Int J Clin Oncol. 2022;27:1725\u201332.","journal-title":"Int J Clin Oncol"},{"key":"20226_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/hepr.70027","volume":"55","author":"T Ishii","year":"2025","unstructured":"Ishii T, Shindoh J, Nakamura I, et al. Impact of surgical resection on hepatocellular carcinoma following systemic drug therapy: a multicenter retrospective observational study. Hepatol Res. 2025;55:1652\u201362.","journal-title":"Hepatol Res"},{"key":"20226_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Ueshima K, Saeki I, et al. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. Liver Cancer. 2024;13:99\u2013112.","journal-title":"Liver Cancer"},{"key":"20226_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117\u201327.","journal-title":"J Clin Oncol"},{"key":"20226_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000531820","volume":"13","author":"M Ikeda","year":"2024","unstructured":"Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. Liver Cancer. 2024;13:193\u2013202.","journal-title":"Liver Cancer"},{"key":"20226_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Galle PR, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with barcelona clinic liver cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2023;12:238\u201350.","journal-title":"Liver Cancer"},{"key":"20226_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109\u201313.","journal-title":"Hepatol Res"},{"key":"20226_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383\u201390.","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"20226_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22\u201331.","journal-title":"Oncology"},{"issue":"6","key":"20226_CR18","first-page":"579","volume":"13","author":"K Akahoshi","year":"2024","unstructured":"Akahoshi K, Shindoh J, Tanabe M, et al. Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the JLCA and JSHBPS expert consensus statement 2023. Liver Cancer. 2024;13(6):579\u201389.","journal-title":"Liver Cancer"},{"key":"20226_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1872-034X.2010.00703.x","volume":"40","author":"Y Kawamura","year":"2010","unstructured":"Kawamura Y, Ikeda K, Hirakawa M, et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res. 2010;40:1006\u201314.","journal-title":"Hepatol Res"},{"key":"20226_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000505190","volume":"9","author":"Y Kawamura","year":"2020","unstructured":"Kawamura Y, Kobayashi M, Shindoh J, et al. Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma may be a useful new predictor of early response to lenvatinib and overall prognosis. Liver Cancer. 2020;9:275\u201392.","journal-title":"Liver Cancer"},{"key":"20226_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"20226_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"20226_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000503577","volume":"9","author":"Y Kawamura","year":"2020","unstructured":"Kawamura Y, Kobayashi M, Shindoh J, et al. (18)F-fluorodeoxyglucose uptake in hepatocellular carcinoma as a useful predictor of an extremely rapid response to lenvatinib. Liver Cancer. 2020;9:84\u201392.","journal-title":"Liver Cancer"},{"key":"20226_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000535514","volume":"13","author":"A Ichida","year":"2024","unstructured":"Ichida A, Arita J, Hatano E, et al. A multicenter phase 2 trial evaluating the efficacy and safety of preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma (LENS-HCC Trial). Liver Cancer. 2024;13:322\u201334.","journal-title":"Liver Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20226-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:51:58Z","timestamp":1789667518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20226-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20226"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20226-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Junichi Shindoh and Yusuke Kawamura receive honoraria from Eisai and Chugai. The other authors have nothing to disclose. This study was supported by a grant from Okinaka Memorial Institute for Medical Disease.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}